Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 10, 2026
Why Is Coherent Corp. (COHR) Stock Down -9.04% Today?

Why Is Coherent Corp. (COHR) Stock Down -9.04% Today?

Key Takeaways

  • Coherent Corp. (COHR) shares tumbled 9.04% in Monday trading, retreating to approximately $344.87 after closing at $379.13 on Friday.
  • Profit-taking dominated following a blistering seven-day winning streak that saw the stock surge roughly 71%, including a 13.4% single-day gain on Friday.
  • De-risking ahead of Wednesday's fiscal Q4 earnings report — due after the market closes on August 12 — added to selling pressure as elevated expectations leave little room for disappointment.
  • Valuation concerns resurfaced after the stock's extraordinary run pushed its trailing P/E ratio well above 150x, far exceeding historical norms and industry peers.
  • Broader optical and AI infrastructure sector weakness weighed on the stock, with peer LITE also declining more than 4% during the session.
  • Traders are closely watching the August 12 earnings release for clarity on AI-driven demand, margin trends, and management's forward guidance for fiscal 2027.

Opening Summary

Shares of Coherent Corp. (COHR), a global leader in photonics, lasers, and optical components serving AI data centers, communications networks, and industrial markets, fell sharply on Monday. The stock declined 9.04%, shedding approximately $34.26 to trade near $344.87, compared with Friday's closing price of $379.13. The selloff marked an abrupt reversal from the prior week's euphoric rally, driven overwhelmingly by profit-taking after a historic run-up, pre-earnings positioning anxiety, and a broader cooling in the high-flying AI infrastructure trade.

Profit-Taking After a Historic Rally

The single most powerful force behind Monday's drop was straightforward profit-taking. COHR had just completed a remarkable seven-day winning streak that added approximately 71% to its market value, culminating in a stunning 13.4% surge on Friday alone. Over that stretch, the company added roughly $30 billion in market capitalization, pushing its total valuation above $70 billion. After a move of that magnitude and velocity, a sharp pullback is not unusual — particularly as short-term traders and momentum-driven funds lock in gains. Monday's decline, while sizable, represents only a partial retracement of the prior week's extraordinary gains.

De-Risking Ahead of the August 12 Earnings Report

With Coherent scheduled to report fiscal fourth-quarter and full-year 2026 results after the closing bell on Wednesday, August 12, traders are reducing exposure ahead of a high-stakes event. The company guided for Q4 revenue between $1.91 billion and $2.05 billion with adjusted EPS of $1.52 to $1.72. However, unofficial "whisper numbers" have crept above the consensus midpoint, raising the bar for what constitutes a positive surprise. This dynamic is especially potent given the stock's recent history: after its fiscal Q3 report in May, COHR fell 7.4% in a single day despite beating estimates on both revenue and earnings. That precedent has made traders cautious about holding elevated positions into another print.

Valuation Concerns Resurface

After its torrid rally, COHR trades at a trailing price-to-earnings multiple north of 150x — dramatically above the S&P 500 median of roughly 23x and its own five-year median of approximately 59x. Even on a forward basis, the stock fetches roughly 45x earnings, a premium that prices in flawless execution and sustained AI-driven growth for years to come. Monday's pullback reflects a recalibration of that risk-reward calculus, particularly as investors weigh execution risks tied to the company's aggressive capacity expansion and heavy capital spending on new manufacturing facilities. Free cash flow turned sharply negative in the most recent quarter as the company ramped its indium phosphide and silicon carbide production lines, and any delay in scaling those projects could push out the expected payoff.

Sector-Wide Weakness in AI Optics Names

COHR did not fall in isolation. Lumentum Holdings (LITE), a close peer in the optical networking and photonics space, declined more than 4.6% on Monday, confirming that selling pressure extended across the AI optics and data-center infrastructure sector. Broader macro headwinds — including sharp selloffs in Asian equity markets and rising U.S. Treasury yields — compounded the negative sentiment. The S&P 500 was essentially flat during the session, underscoring that the weakness was concentrated in the high-beta, high-momentum names that had led the market higher in prior weeks.

Market Context and Trading Activity

Trading volume in COHR was elevated, consistent with the heightened volatility that typically accompanies both post-rally profit-taking and pre-earnings positioning. The stock's beta of approximately 2.1 means it tends to move roughly twice as much as the broader market, amplifying both upside and downside swings. Monday's decline pushed COHR below several short-term technical levels established during last week's rally, though the stock remains substantially above its 50-day and 200-day moving averages. The options market showed heavy put open interest concentrated at the $240 and $300 strike levels, with a strong call wall at $400 serving as overhead resistance.

What Comes Next for COHR

All eyes now turn to Wednesday's earnings report. Investors will be scrutinizing not just the headline numbers but also gross margins — management guided for 39% to 41% — as evidence that capacity expansion is translating into sustainable profitability. Commentary on Nvidia-related orders, demand for 800-gigabit and 1.6-terabit optical transceivers, and progress on the company's CHIPS Act-funded manufacturing expansion will be critical. Additionally, any update on how the proposed FCC restrictions on Chinese optical transceivers could affect Coherent's competitive positioning will be closely parsed. Risks include potential disappointment on forward guidance, slower-than-expected hyperscale data-center spending, and ongoing free-cash-flow pressure during the capital-intensive buildout phase. The stock's outsized rally means the margin for error is razor-thin heading into the print.

Trending AI Robots

For traders seeking systematic, data-driven approaches to navigating volatile stocks like COHR, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of automated trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this dynamic, regularly updated section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore diverse algorithmic approaches. Explore the Trending AI Robots to discover which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: COHR

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


COHR in upward trend: price rose above 50-day moving average on August 07, 2026

COHR moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend. In of 27 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on COHR as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for COHR just turned positive on August 04, 2026. Looking at past instances where COHR's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where COHR advanced for three days, in of 339 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The 10-day moving average for COHR crossed bearishly below the 50-day moving average on July 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where COHR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

COHR broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for COHR entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. COHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.949) is normal, around the industry mean (4.516). P/E Ratio (180.538) is within average values for comparable stocks, (88.474). COHR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.191). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (10.352) is also within normal values, averaging (30.494).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Industry description

This industry manufactures electronic products used in various critical and sophisticated technologies, including laser-based systems, circuit and continuity testers, electro-optical measuring instruments and high-speed precision weighing and inspection equipment. Some major companies operating in this business are Canon Inc., Keysight Technologies Inc., and Fortive Corp.

Market Cap

The average market capitalization across the Electronic Equipment/Instruments Industry is 9.61B. The market cap for tickers in the group ranges from 27.54K to 122.53B. KYCCF holds the highest valuation in this group at 122.53B. The lowest valued company is CSEC at 27.54K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Equipment/Instruments Industry was 2%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 8%. COHR experienced the highest price growth at 44%, while MVIS experienced the biggest fall at -94%.

Volume

The average weekly volume growth across all stocks in the Electronic Equipment/Instruments Industry was -50%. For the same stocks of the Industry, the average monthly volume growth was 56% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 55
Price Growth Rating: 50
SMR Rating: 79
Profit Risk Rating: 77
Seasonality Score: -10 (-100 ... +100)
View a ticker or compare two or three
COHR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a maker of laser diodes and other laser equipment

Industry ElectronicEquipmentInstruments

Profile
Details
Industry
Electronic Equipment Or Instruments
Address
375 Saxonburg Boulevard
Phone
+1 724 352-4455
Employees
26622
Web
https://www.ii-vi.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Why Is Coherent Corp. (COHR) Stock Down -9.04% Today?